Episode Details

Stopping Ozempic rebounds heart risk — and that's a direct opening for supplement brands. Plus AB InBev is moving into functional beverages, and when the world's largest brewer shifts, shelf space shifts with it.

In this episode:

• A large new study finds cardiovascular risk — including heart attack and stroke — rebounds surprisingly quickly after patients stop GLP-1 drugs like Ozempic and Wegovy, strengthening the commercial case for supplement brands positioned around metabolic continuity and heart health.
• Impossible Foods has entered UK retail grocery for the first time with product formats developed specifically for British consumers, making a high-stakes bet that it can revive a plant-based category that saw sharp volume declines across European supermarkets.
• AB InBev, the world's largest brewer behind Stella Artois and Corona, has publicly signalled it is actively seeking growth in new categories including functional and better-for-you beverages, as traditional beer volumes fall across key European markets.
• Biophysical Therapeutics has launched IF1, a new skincare brand built on longevity science from its own laboratory, positioning at the intersection of clinical research and luxury consumer wellness as biotech companies increasingly move into direct-to-consumer health products.

The Health Marketing Daily is a concise briefing for marketers and founders in supplements, functional food and consumer health, hosted by Marco & Klara. New episode every day.

Enjoying the show? A quick rating or review on Apple Podcasts or Spotify helps other marketers find us.

Also from Marco & Klara: The FMCG Marketing Daily · The Digital Commerce Daily